Citation Impact
Citing Papers
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
2011 Standout
In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase
2009
V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
2009
In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
2009
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
2014
Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung
2008
Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
2013
Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets
2004 Standout
Genome-Wide Identification and Testing of Superior Reference Genes for Transcript Normalization in Arabidopsis
2005 Standout
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma
2015
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
2009 StandoutScience
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
2011
Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non–Small Cell Lung Cancer from Patients with Nonmalignant Lung Disease
2009
Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors
2009
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma
2007
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
2010
Hallmarks of Cancer: The Next Generation
2011 Standout
DNA methylation arrays as surrogate measures of cell mixture distribution
2012 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
Angiogenesis in pre-malignant conditions
2009
Quantification of mRNA using real-time RT-PCR
2006 Standout
Establishing the Diagnosis of Lung Cancer
2013 Standout
Hepatocellular carcinoma
2016 Standout
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
2011
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data
2009 Standout
Lung Cancer
2008 Standout
Melanoma: New Insights and New Therapies
2012
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum
2007
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Molecular Biology of Lung Cancer
2013
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Targeting Mutant BRAF in Melanoma
2012
Lung cancer: current therapies and new targeted treatments
2016 Standout
DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
2008
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
2012
A Translational View of the Molecular Pathogenesis of Lung Cancer
2007
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance
2007
Cancer epigenetics reaches mainstream oncology
2011
Epidemiology of Lung Cancer
2013
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis
2010
MicroRNAs in body fluids—the mix of hormones and biomarkers
2011
Circulating mutant DNA to assess tumor dynamics
2008 Standout
Non-coding RNAs in human disease
2011 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Integrating the MicroRNome into the Study of Lung Disease
2008
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
2011
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
2012
Pancreatic Cancer
2010 Standout
Prospects for MEK inhibitors for treating cancer
2014
ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer
2014
MS-qFRET: A quantum dot-based method for analysis of DNA methylation
2009
Cancer/testis antigens, gametogenesis and cancer
2005 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Targeting the RAS pathway in melanoma
2011
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
The PI3K Pathway in Human Disease
2017 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients
2010
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
2010
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Slaying RAS with a synthetic lethal weapon
2010 StandoutNobel
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
2009
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
2011
Nanoparticle-Based Bio-Bar Codes for the Ultrasensitive Detection of Proteins
2003 StandoutScience
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
2015
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems
2002 Standout
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
2002
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
2010
Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
2010
Metabolic reprogramming and cancer progression
2020 StandoutScience
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
2011
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
2009
Cancer Genome Landscapes
2013 StandoutScience
UV Radiation and the Skin
2013 Standout
Cancer Epigenetics: Modifications, Screening, and Therapy
2007
Integrating mechanisms of pulmonary fibrosis
2011 Standout
Works of Jerry Haney being referenced
Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis
2004
KRAS Mutation
2009
One-Step Duplex Reverse Transcription–Polymerase Chain Reaction for Quantitative Assessment of RNA Degradation
2001
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
2008
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
2013
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
2008
Promoter Hypermethylation of Multiple Genes in Sputum Precedes Lung Cancer Incidence in a High-Risk Cohort
2006